Income Taxes (Tables)
|
12 Months Ended |
Dec. 31, 2024 |
| Income Tax Disclosure [Abstract] |
|
| Schedule of Income Tax Expense (Benefit) |
The
Company recorded the below income tax expense (benefit) attributable to income from continuing operations for the year ending December
31, 2024 and December 31, 2023 as follows:
Schedule of Income Tax Expense (Benefit)
| | |
| | | |
| | |
| | |
December
31, | |
| | |
2024 | | |
2023 | |
| | |
(In
thousands, except percentages) | |
| Current | |
| | | |
| | |
| Federal | |
$ | (7 | ) | |
$ | - | |
| State | |
| 21 | | |
| - | |
| Foreign | |
| (34 | ) | |
| - | |
| Current,
Total | |
| (20 | ) | |
| - | |
| Deferred | |
| | | |
| | |
| Federal | |
| - | | |
| - | |
| State | |
| - | | |
| - | |
| Foreign | |
| - | | |
| - | |
| Deferred,
Total | |
| - | | |
| - | |
| Total
income tax expense | |
$ | (20 | ) | |
$ | - | |
|
| Schedule of Effective Income Tax Rate Reconciliation |
The
reconciliation of the provision computed at the federal statutory rate to the Company’s provision (benefit) for income taxes as
follows:
Schedule of Effective Income Tax Rate Reconciliation
| | |
| | | |
| | | |
| | | |
| | |
| | |
December
31, | |
| | |
2024 | | |
2023 | |
| | |
(In
thousands, except percentages) | |
| Tax
at federal statutory rate | |
$ | (15,432 | ) | |
| (21.0 | )% | |
$ | (28,354 | ) | |
| (21.0 | )% |
| State,
net of federal benefit | |
| 12,779 | | |
| 17.4 | % | |
| (6,507 | ) | |
| (4.8 | )% |
| Stock
based compensation | |
| 3,327 | | |
| 3.8 | % | |
| 967 | | |
| 0.7 | % |
| Fair value adjustments | |
| (7,593 | ) | |
| (9.6 | )% | |
| (3,555 | ) | |
| (2.4 | )% |
| Research
and development credits | |
| — | | |
| — | % | |
| (1,121 | ) | |
| (0.8 | )% |
| Section
382 Limitation | |
| 14,583 | | |
| 19.8 | % | |
| | | |
| | |
| Other | |
| (745 | ) | |
| (1.0 | )% | |
| 675 | | |
| 0.2 | % |
| Change
in valuation allowance | |
| (6,939 | ) | |
| (9.4 | )% | |
| 37,895 | | |
| 28.1 | % |
| Total
provision for income taxes | |
$ | (20 | ) | |
| — | % | |
$ | — | | |
| — | % |
|
| Schedule of Components of Deferred Tax Assets and Liabilities |
Schedule
of Components of Deferred Tax Assets and Liabilities
| | |
| | | |
| | |
| | |
December
31, | |
| | |
2024 | | |
2023 | |
| | |
(In
thousands) | |
| Deferred
tax assets | |
| | | |
| | |
| Net
operating loss carryforwards | |
$ | 81,649 | | |
$ | 91,668 | |
| Research
and development tax credits | |
| 5,086 | | |
| 12,087 | |
| Stock
based compensation | |
| 5,866 | | |
| 6,162 | |
| Lease
liability | |
| 2,632 | | |
| 3,098 | |
| Section
174 research and development capitalization | |
| 10,691 | | |
| 11,641 | |
| Interest
expense | |
| 7,157 | | |
| 3,063 | |
| Other
timing differences | |
| 8,754 | | |
| 1,408 | |
| Total
deferred tax assets | |
$ | 121,835 | | |
$ | 129,127 | |
| Valuation
allowance | |
$ | (118,783 | ) | |
$ | (125,722 | ) |
| Net
deferred tax assets | |
$ | 3,052 | | |
$ | 3,405 | |
| | |
| | | |
| | |
| Deferred
tax liabilities | |
| | | |
| | |
| Fixed
assets and intangibles | |
$ | (299 | ) | |
$ | (364 | ) |
| Right
of use assets | |
$ | (2,753 | ) | |
$ | (3,041 | ) |
| Total
deferred tax liabilities | |
$ | (3,052 | ) | |
$ | (3,405 | ) |
| Net
deferred tax assets | |
$ | — | | |
$ | — | |
|
| Schedule of Unrecognized Tax Benefits Roll Forward |
A
reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:
Schedule of Unrecognized Tax Benefits Roll Forward
| | |
| | | |
| | |
| | |
December
31, | |
| | |
2024 | | |
2023 | |
| | |
(In
thousands) | |
| Balance
at beginning of year | |
$ | 6,060 | | |
$ | 4,750 | |
| Additions
based on tax positions related to the current year | |
| (3,301 | ) | |
| 1,310 | |
| Balance
at end of year | |
$ | 2,759 | | |
$ | 6,060 | |
|